Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dofetilide

FDA-approved product (capsule, oral), marketed as Dofetilde, Dofetilide, Tikosyn.

Registered studies
22
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dofetilide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrial fibrillation
  • Atrial flutter
  • Cardiac arrhythmia
  • Ventricular arrhythmia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiarrhythmics, class iii
FDA pharmacologic class
Antiarrhythmic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA23.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

22registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dofetilide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dofetilide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control

    NCT06783868 · start 2025-10

    Registered record
    Registry ID
    NCT06783868
    Conditions
    Atrial Fibrillation; Stroke
    Interventions
    Catheter Ablation; Market-approved AVNB, OAC and AAD
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-10
    Completion
    2027-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Stroke
    InterventionCatheter Ablation; Market-approved AVNB, OAC and AAD
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

    NCT06096337 · start 2023-12-28

    Registered record
    Registry ID
    NCT06096337
    Conditions
    Persistent Atrial Fibrillation
    Interventions
    FARAPULSE™ Pulsed Field Ablation (PFA) System; Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2023-12-28
    Completion
    2028-02-04
    Enrolment
    484

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPersistent Atrial Fibrillation
    InterventionFARAPULSE™ Pulsed Field Ablation (PFA) System; Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
    PhaseNot applicable
    Registry statusActive not recruiting

  • Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).

    NCT05906732 · start 2023-03-12

    Registered record
    Registry ID
    NCT05906732
    Conditions
    Long QT Syndrome
    Interventions
    LQT-1213; Placebo; Dofetilide 250 μg Cap
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2023-03-12
    Completion
    2024-05-31
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong QT Syndrome
    InterventionLQT-1213; Placebo; Dofetilide 250 μg Cap
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

    NCT05034432 · start 2022-05-27

    Registered record
    Registry ID
    NCT05034432
    Conditions
    Arrythmia; Cardiomyopathies
    Interventions
    Intra-Op Prophylactic VT ablation; Conventional Management
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-05-27
    Completion
    2027-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArrythmia; Cardiomyopathies
    InterventionIntra-Op Prophylactic VT ablation; Conventional Management
    PhasePhase 4
    Registry statusRecruiting

  • First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)

    NCT04037397 · start 2019-09-24

    Registered record
    Registry ID
    NCT04037397
    Conditions
    Atrial Fibrillation
    Interventions
    Anti Arrhythmics; Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-24
    Completion
    2024-10-01
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionAnti Arrhythmics; Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation
    PhasePhase 3
    Registry statusCompleted

  • Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients

    NCT04128878 · start 2019-05-01

    Registered record
    Registry ID
    NCT04128878
    Conditions
    Atrial Fibrillation
    Interventions
    Sotalol; Dofetilide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-05-01
    Completion
    2020-12-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionSotalol; Dofetilide
    PhaseNot recorded
    Registry statusCompleted

  • CiPA Phase 1 ECG Biomarker Validation Study

    NCT03070470 · start 2017-03-14

    Registered record
    Registry ID
    NCT03070470
    Conditions
    Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
    Interventions
    Ranolazine; Verapamil; Lopinavir / Ritonavir; Chloroquine; Placebo; Dofetilide and Diltiazem
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-14
    Completion
    2017-06-26
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
    InterventionRanolazine; Verapamil; Lopinavir / Ritonavir; Chloroquine +2 more
    PhasePhase 1
    Registry statusCompleted

  • PVI Using Cryoablation Alone in Paroxysmal AF Patients Converted From Persistent AF With Dofetilide

    NCT01877486 · start 2016-01

    Registered record
    Registry ID
    NCT01877486
    Conditions
    Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation
    Interventions
    Ablation
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2016-01
    Completion
    2016-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Atrial Fibrillation; Persistent Atrial Fibrillation
    InterventionAblation
    PhaseNot recorded
    Registry statusWithdrawn

  • Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

    NCT02365532 · start 2015-02

    Registered record
    Registry ID
    NCT02365532
    Conditions
    Long QT Syndrome
    Interventions
    GS-6615; Placebo to match GS-6615; Placebo to match dofetilide; Dofetilide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-02
    Completion
    2015-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong QT Syndrome
    InterventionGS-6615; Placebo to match GS-6615; Placebo to match dofetilide; Dofetilide
    PhasePhase 1
    Registry statusCompleted

  • Using Smart Phone Technology in Detecting the Presence of Atrial Fibrillation

    NCT02214069 · start 2014-08

    Registered record
    Registry ID
    NCT02214069
    Conditions
    Atrial Fibrillation; Atrial Flutter
    Interventions
    Record and transmit heart rhythm
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-08
    Completion
    2017-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Atrial Flutter
    InterventionRecord and transmit heart rhythm
    PhaseNot recorded
    Registry statusCompleted

  • Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block

    NCT02308748 · start 2014-05

    Registered record
    Registry ID
    NCT02308748
    Conditions
    Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
    Interventions
    Dofetilide; Mexiletine; Lidocaine; Moxifloxacin; Diltiazem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-06
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
    InterventionDofetilide; Mexiletine; Lidocaine; Moxifloxacin +2 more
    PhasePhase 1
    Registry statusCompleted

  • Genetics of QT Prolongation With Antiarrhythmics

    NCT02439658 · start 2014-01

    Registered record
    Registry ID
    NCT02439658
    Conditions
    Long QT Syndrome; Drug Toxicity
    Interventions
    Dofetilide and/or sotalol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2023-04-30
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong QT Syndrome; Drug Toxicity
    InterventionDofetilide and/or sotalol
    PhaseNot recorded
    Registry statusUnknown

  • Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients

    NCT02241252 · start 2013-09

    Registered record
    Registry ID
    NCT02241252
    Conditions
    Cardiac Arrhythmia; Qt Interval, Variation in
    Interventions
    iPhone ECG
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-09
    Completion
    2015-05
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Arrhythmia; Qt Interval, Variation in
    InterventioniPhone ECG
    PhaseNot applicable
    Registry statusCompleted

  • Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects

    NCT01873950 · start 2013-05

    Registered record
    Registry ID
    NCT01873950
    Conditions
    Drug-induced Surface ECG Changes
    Interventions
    Ranolazine; Dofetilide; Verapamil; Quinidine sulfate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-05
    Completion
    2014-12
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-induced Surface ECG Changes
    InterventionRanolazine; Dofetilide; Verapamil; Quinidine sulfate +1 more
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF

    NCT01877473 · start 2013-05

    Registered record
    Registry ID
    NCT01877473
    Conditions
    Persistent Atrial Fibrillation
    Interventions
    Ablation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2013-05
    Completion
    2013-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPersistent Atrial Fibrillation
    InterventionAblation
    PhasePhase 4
    Registry statusWithdrawn